Optimizing biologically targeted clinical trials for neurofibromatosis

David H. Gutmann, Jaishri Blakeley, Bruce R. Korf, Roger J. Packer

Research output: Contribution to journalArticle

Abstract

Introduction: The neurofibromatoses (neurofibromatosis type 1, NF1 and neurofibromatosis type 2, NF2) comprise the most common inherited conditions in which affected children and adults develop tumors of the central and peripheral nervous system. In this review, the authors discuss how the establishment of the Neurofibromatosis Clinical Trials Consortium (NFCTC) has positively impacted on the design and execution of treatment studies for individuals with NF1 and NF2. Areas covered: Using an extensive PUBMED search in collaboration with select NFCTC members expert in distinct NF topics, the authors discuss the clinical features of NF1 and NF2, the molecular biology of the NF1 and NF2 genes, the development and application of clinically relevant Nf1 and Nf2 genetically engineered mouse models and the formation of the NFCTC to enable efficient clinical trial design and execution. Expert opinion: The NFCTC has resulted in a more seamless integration of mouse preclinical and human clinical trials efforts. Leveraging emerging enabling resources, current research is focused on identifying subtypes of tumors in NF1 and NF2 to deliver the most active compounds to the patients most likely to respond to the targeted therapy.

Original languageEnglish (US)
Pages (from-to)443-462
Number of pages20
JournalExpert Opinion on Investigational Drugs
Volume22
Issue number4
DOIs
StatePublished - Apr 2013

Fingerprint

Neurofibromatoses
Clinical Trials
Neurofibromatosis 1
Nervous System Neoplasms
Neurofibromatosis 2
Peripheral Nervous System
Expert Testimony
Molecular Biology
Central Nervous System
Therapeutics
Research
Genes
Neoplasms

Keywords

  • Clinical trials
  • Mouse models
  • NF1
  • NF2
  • Preclinical

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Optimizing biologically targeted clinical trials for neurofibromatosis. / Gutmann, David H.; Blakeley, Jaishri; Korf, Bruce R.; Packer, Roger J.

In: Expert Opinion on Investigational Drugs, Vol. 22, No. 4, 04.2013, p. 443-462.

Research output: Contribution to journalArticle

Gutmann, David H. ; Blakeley, Jaishri ; Korf, Bruce R. ; Packer, Roger J. / Optimizing biologically targeted clinical trials for neurofibromatosis. In: Expert Opinion on Investigational Drugs. 2013 ; Vol. 22, No. 4. pp. 443-462.
@article{c8512fbfca734a0e8a783f4ba88d07d3,
title = "Optimizing biologically targeted clinical trials for neurofibromatosis",
abstract = "Introduction: The neurofibromatoses (neurofibromatosis type 1, NF1 and neurofibromatosis type 2, NF2) comprise the most common inherited conditions in which affected children and adults develop tumors of the central and peripheral nervous system. In this review, the authors discuss how the establishment of the Neurofibromatosis Clinical Trials Consortium (NFCTC) has positively impacted on the design and execution of treatment studies for individuals with NF1 and NF2. Areas covered: Using an extensive PUBMED search in collaboration with select NFCTC members expert in distinct NF topics, the authors discuss the clinical features of NF1 and NF2, the molecular biology of the NF1 and NF2 genes, the development and application of clinically relevant Nf1 and Nf2 genetically engineered mouse models and the formation of the NFCTC to enable efficient clinical trial design and execution. Expert opinion: The NFCTC has resulted in a more seamless integration of mouse preclinical and human clinical trials efforts. Leveraging emerging enabling resources, current research is focused on identifying subtypes of tumors in NF1 and NF2 to deliver the most active compounds to the patients most likely to respond to the targeted therapy.",
keywords = "Clinical trials, Mouse models, NF1, NF2, Preclinical",
author = "Gutmann, {David H.} and Jaishri Blakeley and Korf, {Bruce R.} and Packer, {Roger J.}",
year = "2013",
month = "4",
doi = "10.1517/13543784.2013.772979",
language = "English (US)",
volume = "22",
pages = "443--462",
journal = "Expert Opinion on Investigational Drugs",
issn = "1354-3784",
publisher = "Taylor and Francis Ltd.",
number = "4",

}

TY - JOUR

T1 - Optimizing biologically targeted clinical trials for neurofibromatosis

AU - Gutmann, David H.

AU - Blakeley, Jaishri

AU - Korf, Bruce R.

AU - Packer, Roger J.

PY - 2013/4

Y1 - 2013/4

N2 - Introduction: The neurofibromatoses (neurofibromatosis type 1, NF1 and neurofibromatosis type 2, NF2) comprise the most common inherited conditions in which affected children and adults develop tumors of the central and peripheral nervous system. In this review, the authors discuss how the establishment of the Neurofibromatosis Clinical Trials Consortium (NFCTC) has positively impacted on the design and execution of treatment studies for individuals with NF1 and NF2. Areas covered: Using an extensive PUBMED search in collaboration with select NFCTC members expert in distinct NF topics, the authors discuss the clinical features of NF1 and NF2, the molecular biology of the NF1 and NF2 genes, the development and application of clinically relevant Nf1 and Nf2 genetically engineered mouse models and the formation of the NFCTC to enable efficient clinical trial design and execution. Expert opinion: The NFCTC has resulted in a more seamless integration of mouse preclinical and human clinical trials efforts. Leveraging emerging enabling resources, current research is focused on identifying subtypes of tumors in NF1 and NF2 to deliver the most active compounds to the patients most likely to respond to the targeted therapy.

AB - Introduction: The neurofibromatoses (neurofibromatosis type 1, NF1 and neurofibromatosis type 2, NF2) comprise the most common inherited conditions in which affected children and adults develop tumors of the central and peripheral nervous system. In this review, the authors discuss how the establishment of the Neurofibromatosis Clinical Trials Consortium (NFCTC) has positively impacted on the design and execution of treatment studies for individuals with NF1 and NF2. Areas covered: Using an extensive PUBMED search in collaboration with select NFCTC members expert in distinct NF topics, the authors discuss the clinical features of NF1 and NF2, the molecular biology of the NF1 and NF2 genes, the development and application of clinically relevant Nf1 and Nf2 genetically engineered mouse models and the formation of the NFCTC to enable efficient clinical trial design and execution. Expert opinion: The NFCTC has resulted in a more seamless integration of mouse preclinical and human clinical trials efforts. Leveraging emerging enabling resources, current research is focused on identifying subtypes of tumors in NF1 and NF2 to deliver the most active compounds to the patients most likely to respond to the targeted therapy.

KW - Clinical trials

KW - Mouse models

KW - NF1

KW - NF2

KW - Preclinical

UR - http://www.scopus.com/inward/record.url?scp=84875170791&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84875170791&partnerID=8YFLogxK

U2 - 10.1517/13543784.2013.772979

DO - 10.1517/13543784.2013.772979

M3 - Article

C2 - 23425047

AN - SCOPUS:84875170791

VL - 22

SP - 443

EP - 462

JO - Expert Opinion on Investigational Drugs

JF - Expert Opinion on Investigational Drugs

SN - 1354-3784

IS - 4

ER -